Our founding scientists include Dr. Bruce German, Dr. David Mills, Dr. Carlito Lebrilla, Dr. Daniela Barile and Dr. Samara Freeman, whose fundamental research and translational clinical trials have been enabled by more than $15 million in federal and private grants since 2004.

Under the leadership of Dr. David Kyle, Evolve completed a $1 million seed funding round in mid-2014, a $9 million Series A round in August 2015, followed by a $20 million Series B capital raise in 2017. Evolve most recently completed a $40M Series C round of funding co-led by the Bill & Melinda Gates Foundation and Horizons Ventures, the venture division of the Li Ka Shing Foundation.

Evolve has successfully completed a milestone proof-of-concept study to demonstrate the efficacy of its initial proprietary offering, with an ongoing series clinical trials taking place across both human and animal health applications. Having led to the development and commercial launch of products to resolve newborn gut dysbiosis, including Evivo® EVC001 for infants and GlycoGuard® for foals, Evolve`s discovery platform is now being applied to solving gut dysbiosis throughout the human and animal life cycle.

With a strong portfolio of intellectual property developed at UC Davis, a world-class management team plus blue-chip investors, and an unwavering dedication to allowing science to direct our product development, Evolve continues to expand it`s pipeline of next generation microbiome-based solutions to establish, restore, and maintain a healthy gut microbiome.

Evolve BioSystems, Inc. Videos

Evivo - Instructions for use. - Video

GlycoGuard Take Control of your Newborn Foal`s Intestinal Health! - Video

Contact supplier